Neuphoria Therapeutics (NEUP) announced that Institutional Shareholders Services, ISS, a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company’s director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital Management is conducting a proxy contest and is seeking the election at the 2025 Annual Meeting of two director candidates in opposition to the highly qualified nominees unanimously recommended by the Neuphoria Board of Directors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright
- Neuphoria Therapeutics responds to Lynx1’s revised indication of interest
- Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1
- Neuphoria Therapeutics urges stockholders to vote for company nominees
- Neuphoria initiates strategic review, confirms receipt of indication of interest